GENEUNIVERSAL INC

GENEUNIVERSAL INC specializes in advanced molecular biology services centered on synthetic DNA technologies, including antibody gene synthesis, subcloning, and plasmid preparation. The company delivers precise, high-fidelity genetic constructs for research and development applications, leveraging molecular cloning techniques, bacterial transformation, and endotoxin-free plasmid purification to support downstream biomedical workflows. Their technical expertise lies in recombinant DNA design, vector engineering, and sequence-verified construct production, enabling clients to accelerate therapeutic discovery and diagnostic development. Differentiators include rigorous quality control protocols for plasmid integrity and purity, ensuring compatibility with in vitro and in vivo expression systems. The contractor has demonstrated direct engagement with the Department of Health and Human Services, providing specialized genetic services critical to immunology and biologics research. This relationship suggests alignment with HHS sub-agencies such as NIH or CDC, where custom gene constructs are essential for vaccine development, monoclonal antibody characterization, and gene expression studies. The nature of the work indicates a trusted vendor role in supporting mission-critical, non-clinical research pipelines requiring high reproducibility and regulatory-grade documentation. GENEUNIVERSAL INC operates primarily under NAICS 541990, which encompasses other professional scientific services not elsewhere classified—specifically, niche biotech R&D support that bridges academic research and federal biodefense or therapeutic programs. Their market positioning is as a specialized contract research provider for molecular biology tasks requiring precision, scalability, and compliance with biosafety standards, serving government-funded life sciences initiatives. As a small business structured as a 2L entity based in Newark, Delaware, GENEUNIVERSAL INC maintains a focused operational footprint with no public certifications on record. The company is positioned as a technical specialist within the federal bioresearch ecosystem, offering tailored genetic services to agencies requiring bespoke DNA construct development without reliance on large-scale manufacturing infrastructure.